On August 25, EVEREST MED rose 5.14% in regular trading, trading at HK$32.56/share, with turnover of HK$118 million. The stock continued its technical recovery following a two-day correction of over 13% from the August 20 single-day surge of more than 41%.

The ongoing momentum stems from dual catalysts: Moderna and Merck's mRNA personalized cancer vaccine intismeran autogene achieved positive results in its first Phase 3 clinical trial for melanoma — a milestone regarded as the first successful late-stage validation of mRNA cancer vaccine technology — and EVEREST MED's H1 earnings significantly beat expectations with revenue of RMB 1.148 billion, up 157% year-over-year, achieving non-IFRS net profit of RMB 97.23 million and turning profitable. Core product Nefecon generated RMB 889 million in sales, up 94%.

A major broker maintained a Buy rating with a target price of HK$66, citing the company's proven commercialization infrastructure and mRNA technology platform as key value drivers.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)